A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

Summary

This is a Phase 1/2, open-label, multi-center, multi-cohort, non-randomized dose escalation and dose expansion basket study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in participants with autoimmune diseases.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Systemic Sclerosis
• Idiopathic Inflammatory Myopathies
• Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
• Rheumatoid Arthritis

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1/2

Ages

18 to 75 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Nkarta, Inc.

Last updated on ClinicalTrials.gov

August 7, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites